Analyzing Silexion Therapeutics (NASDAQ:SLXN) and Apogee Therapeutics (NASDAQ:APGE)

Apogee Therapeutics (NASDAQ:APGE) and Silexion Therapeutics (NASDAQ:SLXN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, profitability and dividends.

Analyst Recommendations

This is a summary of current recommendations for Apogee Therapeutics and Silexion Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	0	0	6	0	3.00
Silexion Therapeutics	0	0	1	0	3.00

Apogee Therapeutics currently has a consensus price target of $92.17, indicating a potential upside of 132.04%. Silexion Therapeutics has a consensus price target of $5.00, indicating a potential upside of 327.35%. Given Silexion Therapeutics’ higher possible upside, analysts plainly believe Silexion Therapeutics is more favorable than Apogee Therapeutics.

Valuation and Earnings

This table compares Apogee Therapeutics and Silexion Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$83.99 million	($3.29)	-12.07
Silexion Therapeutics	N/A	N/A	$260,000.00	N/A	N/A

Profitability

This table compares Apogee Therapeutics and Silexion Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-21.81%	-20.94%
Silexion Therapeutics	N/A	N/A	-249.43%

Volatility & Risk

Apogee Therapeutics has a beta of 2.46, suggesting that its stock price is 146% more volatile than the S&P 500. Comparatively, Silexion Therapeutics has a beta of 0.11, suggesting that its stock price is 89% less volatile than the S&P 500.

Institutional and Insider Ownership

79.0% of Apogee Therapeutics shares are owned by institutional investors. Comparatively, 10.9% of Silexion Therapeutics shares are owned by institutional investors. 36.1% of Apogee Therapeutics shares are owned by company insiders. Comparatively, 33.0% of Silexion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Apogee Therapeutics beats Silexion Therapeutics on 5 of the 8 factors compared between the two stocks.

About Apogee Therapeutics

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

About Silexion Therapeutics

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.